stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) Total debt
DexCom, Inc.'s total debt at the end of fiscal 2025 was $1.2B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from $2.3M (fiscal 2015) to $2.4B (fiscal 2023); the current reading is higher than 64% of that period. DexCom, Inc. ranks 16th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.2B | 0.32% |
| FY2024 | $1.2B | (49.18%) |
| FY2023 | $2.4B | 23.54% |
| FY2022 | $2.0B | (1.62%) |
| FY2021 | $2.0B | 18.92% |
| FY2020 | $1.7B | 56.86% |
| FY2019 | $1.1B | 6.28% |
| FY2018 | $1.0B | 208.39% |
| FY2017 | $327.6M | 5,360.00% |
| FY2016 | $6.0M | 160.87% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $1.2B | 0.07% |
| Jun 2026 | $1.2B | 0.08% |
| Mar 2026 | $1.2B | 0.07% |
| Dec 2025 | $1.2B | 0.08% |
| 39 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BSX Boston Scientific Corporation compare | $12.0B |
| GEHC GE HealthCare Technologies Inc. compare | $11.6B |
| PHG Koninklijke Philips N.V. compare | $8.0B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $7.5B |
| SNN Smith & Nephew SNATS, Inc. compare | $3.2B |
| STE STERIS plc compare | $1.9B |
| DXCM DexCom, Inc. | $1.2B |
| EW Edwards Lifesciences Corporation compare | $598.8M |
| GKOS Glaukos Corporation compare | $66.9M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on DXCM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement